Janux Therapeutics, Inc. (NasdaqGM: JANX)
Health Care · Biotechnology · US
$18.68
+7.42% today · -24.4% 1Y
Janux Therapeutics, Inc. (NasdaqGM: JANX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.06B and employs 113 people.
Over the last twelve months the share price has lost 24.4%, trading between 12.12 and 35.34.
Tweenvest scores Janux Therapeutics, Inc. across four factors: quality 32/100, value 57/100. Its strongest factor is value.
JANX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.06B
- Revenue (TTM)
- $24.00M
- P/E
- —
- EPS
- -1.64
- Dividend yield
- —
- Beta (5Y)
- 2.51
- 52-week high
- $35.34
- 52-week low
- $12.12
- Avg volume (3M)
- —
- Shares outstanding
- 61.14M
- Employees
- 113
- Next earnings
- —
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
- ISIN
- US47103J1051
- Founded
- 2017
- Listed since
- Jun 11, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.